The oral mutant IDH1 inhibitor ivosidenib (AG-120) has demonstrated impressive activity in treating IDH1-mutated acute myeloid leukemia (AML), thus providing an important proof of concept for the therapeutic targeting of IDH1-mutated malignancies14. Here, IDH1 is linked to acute myeloid leukemia.